CLAIMS

5

10

15

20

WHAT IS CLAIMED IS:

- 1. A medical article comprising an implantable substrate having a coating, the coating including an ABA or an AB block copolymer, the block copolymer having moieties A and B, wherein one of the moieties produces a biological response and the other moiety provides the block copolymer with structural functionality.
 - 2. The medical article of Claim 1, wherein the medical article is a stent.
- 3. The medical article of Claim 1, wherein block A is the biological moiety, and block B is the structural moiety.
- 4. The medical article of Claim 1, wherein block B is the biological moiety, and block A is the structural moiety.
- 5. The medical article of Claim 1, wherein the biological moiety is selected from a group consisting of poly(alkylene glycols), poly(ethylene oxide), poly(ethylene oxide-copropylene oxide), poly(N-vinyl pyrrolidone), poly(acrylamide methyl propane sulfonic acid) and salts thereof, sulfonated dextran, polyphosphazenes, poly(orthoesters), poly(tyrosine carbonate), hyaluronic acid, hyaluronic acid having a stearoyl or palmitoyl substitutent group, poly(ethylene glycol)-hyaluronic acid, poly(ethylene glycol)-hyaluronic acid-stearoyl, poly(ethylene glycol)-hyaluronic acid-palmitoyl, heparin, poly(ethylene glycol)-heparin, and copolymers thereof.
- 6. The medical article of Claim 5, wherein the poly(alkylene glycol) is selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene

5

10

20

glycol), a graft copolymer of poly(L-lysine) and poly(ethylene glycol), and copolymers thereof.

- 7. The medical article of Claim 1, wherein the structural moiety comprises poly(caprolactone), poly(butylene terephthalate), poly(ester amide), poly(lactic acid), or copolymers thereof.
- 8. The medical article of Claim 1, wherein the block copolymer is selected from a group consisting of poly(ethylene-glycol)-block-poly(caprolactone)-block-poly(ethylene-glycol)-block poly(caprolactone), poly(ethylene-glycol)-block-poly(ethylene-glycol)-block-poly(ethylene-glycol), poly(butyleneterephthalate)-block-poly(ethylene-glycol), poly(butyleneterephthalate)-block-poly(butyleneterephthalate), poly(ethylene-glycol)-block-poly(butyleneterephthalate), poly(ethylene-glycol)-block-poly (lactic acid)-block-poly(ethylene-glycol), poly (lactic acid)-block-poly(ethylene-glycol)-block-po
- 9. The medical article of Claim 1, additionally comprising a first biologically active agent incorporated into the coating.
 - 10. The medical article of Claim 1, additionally comprising an active agent conjugated to the block copolymer.
 - 11. The medical article of Claim 10, wherein the active agent conjugated to the block copolymer is diazenium diolate.
 - 12. A method for fabricating a medical article, the method including applying a coating on at least a portion of an implantable substrate, the coating including an ABA or an AB block copolymer, wherein one of the moieties in the block copolymer produces a

10

15

biological response and the other moiety provides the block copolymer with structural functionality.

- 13. The method of Claim 12, wherein the medical article is a stent.
- 14. The method of Claim 12, wherein block A is the biological moiety, and block5 B is the structural moiety.
 - 15. The method of Claim 12, wherein block B is the biological moiety, and block A is the structural moiety.
 - 16. The method of Claim 12, wherein the biological moiety is selected from a group consisting of poly(alkylene glycols), poly(ethylene oxide), poly(ethylene oxide-copropylene oxide), poly(N-vinyl pyrrolidone), poly(acrylamide methyl propane sulfonic acid) and salts thereof, sulfonated dextran, polyphosphazenes, poly(orthoesters), poly(tyrosine carbonate), hyaluronic acid, hyaluronic acid having a stearoyl or palmitoyl substitutent group, poly(ethylene glycol)-hyaluronic acid, poly(ethylene glycol)-hyaluronic acid-stearoyl, poly(ethylene glycol)-hyaluronic acid-palmitoyl, heparin, poly(ethylene glycol)-heparin, and copolymers thereof.
 - 17. The method of Claim 16, wherein the poly(alkylene glycol) is selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), a graft copolymer of poly(L-lysine) and poly(ethylene glycol), and copolymers thereof.

- 18. The method of Claim 12, wherein the structural moiety comprises poly(caprolactone), poly(butylene terephthalate), poly(ester amide), poly(lactic acid), or copolymers thereof.
- 19. The method of Claim 12, wherein the block copolymer is selected from a

 5 group consisting of poly(ethylene-glycol)-block-poly(caprolactone)-block-poly(ethyleneglycol), poly(caprolactone)-block-poly(ethylene-glycol)-block poly(caprolactone),
 poly(ethylene-glycol)-block-poly(butyleneterephthalate)-block-poly(ethylene-glycol),
 poly(butyleneterephthalate)-block-poly(ethylene-glycol)-block poly(butyleneterephthalate),
 poly(ethylene-glycol)-block-poly(butyleneterephthalate), poly(ethylene-glycol)-block-poly

 (lactic acid)-block-poly(ethylene-glycol), poly (lactic acid)-block-poly(ethylene-glycol)block-poly(lactic acid) and blends thereof.
 - 20. The method of Claim 12, additionally comprising a first biologically active agent incorporated into the coating.
 - 21. The medical article of Claim 12, additionally comprising an active agent conjugated to the block copolymer.
 - 22. The medical article of Claim 21, wherein the active agent conjugated to the block copolymer is diazenium diolate.
 - 23. A medical article comprising an implantable substrate having a coating, the coating comprising phosphoryl choline or polyaspirin.

15